search
Back to results

Treatment of Non Union of Long Bone Fractures by Autologous Mesenchymal Stem Cell

Primary Purpose

Nonunion Fractures

Status
Completed
Phase
Phase 1
Locations
Iran, Islamic Republic of
Study Type
Interventional
Intervention
cell injection
Sponsored by
Royan Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Nonunion Fractures focused on measuring nonunion fracture bone formation pain relief

Eligibility Criteria

12 Years - 75 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers
  • Inclusion criteria:
  • Both genders are eligible
  • Nonunion or delayed union diagnosed with X-Ray examination.
  • More than 4 cm distance to joint
  • Provided written informed consent
  • Exclusion criteria:
  • Multiple major fracture or untreated major fracture
  • Infected fracture
  • HIV, hepatitis B or hepatitis C infection at the time of screening
  • Pregnant or lactating women
  • Diagnosis of cancer
  • Active treatment with immunosuppressive drugs or anticoagulant agent
  • Known allergic reaction to components of study treatment and/or study injection procedure

Sites / Locations

  • Royan Institute

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

non union

Arm Description

Patients with nonunion fracture of long bones

Outcomes

Primary Outcome Measures

Radiological progression of bone fusion
callus formation in fracture zone

Secondary Outcome Measures

Reduction of pain using VAS
Patients feel less pain during use of fractured limb
Cost analysis based on length of hospital stay
Cost benefit of cell transplantation by reduction of hospital admission time

Full Information

First Posted
September 20, 2010
Last Updated
December 13, 2011
Sponsor
Royan Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT01206179
Brief Title
Treatment of Non Union of Long Bone Fractures by Autologous Mesenchymal Stem Cell
Official Title
Effect of Bone Marrow-derived Mesenchymal Stem Cell Transplantation in Reconstructing Human Bone Defects
Study Type
Interventional

2. Study Status

Record Verification Date
June 2008
Overall Recruitment Status
Completed
Study Start Date
March 2009 (undefined)
Primary Completion Date
March 2011 (Actual)
Study Completion Date
May 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Royan Institute

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Treatment of nonunion, delayed union and malunion fractures of long bones remains problematic. The definition of nonunion is a failure of the fracture to heal in six months in a patient in whom progressive repair had not been observed radiographically between the third and sixth month after the fracture. First of all good surgical techniques are stable immobilization must be obtained and local sepsis excluded. Then stimulation of the callus is required. Numerous techniques have been developed ranging from invasive interventions (including internal fixation with the use of bone graft or bone graft substitutes) to non invasive procedures (ultrasound and pulsed electromagnetic fields). Recently, autologous cell therapy was presented as an interesting approach. The concept of such therapies is based on the effect of stem cells presented in the bone marrow and able to be transformed in osteoblast cells. The purpose of this study is to find if mesenchymal stem cells can stimulate bone regeneration in nonunion and delayed union fractures to reduce later surgeries required to augment the healing process and to accelerate the time to healing.
Detailed Description
Treatment of nonunion, delayed union and malunion fractures of long bones remains problematic. The definition of nonunion is a failure of the fracture to heal in six months in a patient in whom progressive repair had not been observed radiographically between the third and sixth month after the fracture. Nonunion is a serious complication of a fracture, occurring in 2-10% of patients, as it is associated with high economic and health burden. Many cases are subsequently approached by multiple surgical and nonsurgical modalities. Various devices, under the name of "bone growth stimulators" have been used to enhance healing of the fracture. Recent studies, demonstrated the efficacy of mesenchymal stem cells in regeneration of bone and cartilage tissue. In this study percutaneous injection of mesenchymal stem cells to the site of fracture is performed as an outpatient procedure or during an operative exposure to evaluate its efficacy in enhancing bone regeneration. In the case of small size of bone gap, mesenchymal stem cells are injected into the callus of fracture site through an outpatient procedure under the guide of fluoroscopy. If there is a large bone gap, through a surgical management, mesenchymal stem cells seeded on bone matrix are placed at the site of fracture. Patients are followed by X-Ray examination 1,2,6, and 12 months after treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Nonunion Fractures
Keywords
nonunion fracture bone formation pain relief

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
6 (Actual)

8. Arms, Groups, and Interventions

Arm Title
non union
Arm Type
Experimental
Arm Description
Patients with nonunion fracture of long bones
Intervention Type
Biological
Intervention Name(s)
cell injection
Other Intervention Name(s)
Cell transplantation
Intervention Description
Injection of mesenchymal cells in fractured zone
Primary Outcome Measure Information:
Title
Radiological progression of bone fusion
Description
callus formation in fracture zone
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Reduction of pain using VAS
Description
Patients feel less pain during use of fractured limb
Time Frame
6 months
Title
Cost analysis based on length of hospital stay
Description
Cost benefit of cell transplantation by reduction of hospital admission time
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Both genders are eligible Nonunion or delayed union diagnosed with X-Ray examination. More than 4 cm distance to joint Provided written informed consent Exclusion criteria: Multiple major fracture or untreated major fracture Infected fracture HIV, hepatitis B or hepatitis C infection at the time of screening Pregnant or lactating women Diagnosis of cancer Active treatment with immunosuppressive drugs or anticoagulant agent Known allergic reaction to components of study treatment and/or study injection procedure
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hamid Gourabi, PhD
Organizational Affiliation
President of Royan Institute
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Mohammad reza Baghban Eslami Nejad, PhD
Organizational Affiliation
Sientific Board
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Mohssen Emadeddin, MD
Organizational Affiliation
Orthopadic Investigator
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Nasser Aghdami, MD,PhD
Organizational Affiliation
Head of Regenerative center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ahmad Vosough, MD
Organizational Affiliation
Radiologist investigator
Official's Role
Principal Investigator
Facility Information:
Facility Name
Royan Institute
City
Tehran
Country
Iran, Islamic Republic of

12. IPD Sharing Statement

Citations:
PubMed Identifier
28367426
Citation
Emadedin M, Labibzadeh N, Fazeli R, Mohseni F, Hosseini SE, Moghadasali R, Mardpour S, Azimian V, Goodarzi A, Ghorbani Liastani M, Mirazimi Bafghi A, Baghaban Eslaminejad M, Aghdami N. Percutaneous Autologous Bone Marrow-Derived Mesenchymal Stromal Cell Implantation Is Safe for Reconstruction of Human Lower Limb Long Bone Atrophic Nonunion. Cell J. 2017 Apr-Jun;19(1):159-165. doi: 10.22074/cellj.2016.4866. Epub 2016 Dec 21.
Results Reference
derived
PubMed Identifier
27602311
Citation
Labibzadeh N, Emadedin M, Fazeli R, Mohseni F, Hosseini SE, Moghadasali R, Mardpour S, Azimian V, Ghorbani Liastani M, Mirazimi Bafghi A, Baghaban Eslaminejad M, Aghdami N. Mesenchymal Stromal Cells Implantation in Combination with Platelet Lysate Product Is Safe for Reconstruction of Human Long Bone Nonunion. Cell J. 2016 Fall;18(3):302-309. doi: 10.22074/cellj.2016.4557. Epub 2016 Aug 24.
Results Reference
derived
Links:
URL
http://www.royaninstitute.org
Description
Related Info

Learn more about this trial

Treatment of Non Union of Long Bone Fractures by Autologous Mesenchymal Stem Cell

We'll reach out to this number within 24 hrs